563 related articles for article (PubMed ID: 6414759)
1. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
2. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women.
Cekan SZ; Jia M; Landgren BM; Diczfalusy E
Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
4. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days.
Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM
Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792
[TBL] [Abstract][Full Text] [Related]
5. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
Hammond GL; Langley MS; Robinson PA; Nummi S; Lund L
Fertil Steril; 1984 Jul; 42(1):44-51. PubMed ID: 6233179
[TBL] [Abstract][Full Text] [Related]
6. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
[TBL] [Abstract][Full Text] [Related]
7. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel.
Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E
Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664
[TBL] [Abstract][Full Text] [Related]
8. Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets.
Abdalla KA; Shabaan MM; Stanczyk FZ
Contraception; 1992 Feb; 45(2):111-8. PubMed ID: 1559334
[TBL] [Abstract][Full Text] [Related]
9. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
Rossmanith WG; Steffens D; Schramm G
Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
[TBL] [Abstract][Full Text] [Related]
10. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
Shumin X; Johannisson E; Landgren BM; Diczfalusy E
Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
[TBL] [Abstract][Full Text] [Related]
11. Effect of some oral contraceptives on serum concentrations of sex hormone binding globulin and ceruloplasmin.
Song S; Chen JK; He ML; Fotherby K
Contraception; 1989 Apr; 39(4):385-99. PubMed ID: 2498034
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
14. Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol.
Crona N; Silfverstolpe G; Samsioe G
Contraception; 1984 Mar; 29(3):261-70. PubMed ID: 6234148
[TBL] [Abstract][Full Text] [Related]
15. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
Goebelsmann U; Mashchak CA; Mishell DR
Am J Obstet Gynecol; 1985 Apr; 151(7):868-77. PubMed ID: 3920910
[TBL] [Abstract][Full Text] [Related]
17. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
20. Effect of two oral contraceptives containing ethinylestradiol and gestodene or norgestimate upon androgen parameters and serum binding proteins.
Wiegratz I; Jung-Hoffmann C; Kuhl H
Contraception; 1995 Jun; 51(6):341-6. PubMed ID: 7554973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
